Interaction of palmitic acid with losartan potassium at the binding sites of bovine serum albumin

Authors

  • A Ferdosi Kabir Department of Pharmacy, The University of Asia Pacific, Dhaka-1209, Bangladesh
  • K Nazim Uddin Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Dhaka, Dhaka-1000, Bangladesh
  • A.F.M Nazmus Sadat Department of Pharmacy, The University of Asia Pacific, Dhaka-1209, Bangladesh
  • Hossain Mahboob Department of Pharmacy, The University of Asia Pacific, Dhaka-1209, Bangladesh
  • Md Abdul Mazid Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Dhaka, Dhaka-1000, Bangladesh

Keywords:

Losartan potassium, palmitic acid, bovine serum albumin, equilibrium dialysis, binding sites

Abstract

The binding of losartan potassium, an angiotensin II receptor antagonist, to bovine serum albumin wasstudied by equilibrium dialysis method (ED) in presence or absence of palmitic acid. The study wascarried out using ranitidine and diazepam as site-1 and site-2 specific probe, respectively. Differentanalysis of binding of losartan to bovine serum albumin suggested two sets of association constants:high affinity association constant (k1 = 11.2 x 105 M-1) with low capacity (n1 = 2) and low affinityassociation (k2 = 2. 63 x 105 M-1) constant with high capacity (n2 = 10) at pH 7.4 and 27°C. Duringconcurrent administration of palmitic acid and losartan potassium in presence or absence of ranitidineor diazepam, it was that found that palmitic acid causes the release of losartan potassium from itsbinding site on BSA resulting reduced binding of losartan potassium to BSA. The increment in freefraction of losartan potassium was from 13.1% to 47.2 % upon the addition of increased concentrationof only palmitic acid at a concentration of 0 x 10-5 M to 16 x 10-5 M. In presence of ranitidine ordiazepam as site specific probes, palmitic acid further increases the free fraction of losartan potassiumwere from 22.8% to 53.4% and 35.3 to 65.5%, respectively. This data provided the evidence ofinteraction of higher concentration of palmitic acid at the binding sites on BSA changing thepharmacokinetics properties of losartan potassium

Downloads

Download data is not yet available.

References

Kragh-Hansen, U. Molecular aspects of ligand binding to serum albumin. J. The American Society for Pharmacology and Experimental Therapeutics. 1981a. 33:17-46.

He, X.M. and Carter, D.C. Atomic structure and chemistry of human serum albumin. Nature. 1992, 358:209-215.

Sudlow, G., Birkett, D.J. and Wade, D.N. The characterization of two specific binding sites on human serum albumin. Mol. Pharmacol., 1975, 11:824-832.

Sudlow, G., Birkett, D.J. and Wade D.N. Further characterization of two specific binding sites on human serum albumin. Mol. Pharmacol., 1976, 12:1052-1061.

Jiunn, H. L., David, M. C. and Daniel, E. D. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clinical Pharmacokinetics. 1987, 12, 402-432.

Rahman, M. H., Yamasaki, K., Shin,Y. H., Lin, C. C., and Otagirin, M., Characterization of high affinity binding sites of non-steroidal anti-inflammatory drugs with respect to site-specific probes on human serum albumin. Biol Pharm Bull., 1993, 16(11):1169-1174.

Kragh-Hansen, U. Effect of aliphatic fatty acids on the binding of Phenol Red to human serum albumin. Biochem. J. 1981b, 195:603-613.

Horiuchi, T., Johno, I., Hasegawa, T., Kitazawa. S., Goto, M. and Hata T. Inhibitory Effect of Free Fatty Acids on Plasma Protein Binding of Disopyramide in Haemodialysis Patients. Eur J Clin Pharmacol 1989, 36:175-180.

Cunningham, V. J., Gay, L. and Sttoner, H. B. The binding of L-tryptophan to serum albumins in the presence of non-esterified fatty acids. Biochem. J. 1975, 146:653-658.

Goodman, D.S. : The interaction of human serum albumin with long chain fatty acid anions. J.Am, Chem Soc. 1958, 80:3892-3898.

Spector AA. Fatty acid binding to plasma albumin. J Lipid Res. 1975, 16(3):165-179. Links

Ashbrook JD, Spector AA, Santos EC, Fletcher JE. Long chain fatty acid binding to human plasma albumin. J Biol Chem. 1975, 250(6):2333-2338.

Christ DD. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol. 1995, 35(5):515-520.

Downloads

Published

2010-03-10

How to Cite

1.
Ferdosi Kabir A, Nazim Uddin K, Nazmus Sadat A, Mahboob H, Abdul Mazid M. Interaction of palmitic acid with losartan potassium at the binding sites of bovine serum albumin. Ars Pharm [Internet]. 2010 Mar. 10 [cited 2024 Dec. 26];51(1):28-36. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/4843

Issue

Vol. 51 No. 1 (2010)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).